Due to the prevalence of the PI3K‐Akt pathway in tumorigenesis and its criticality to the development of ccRCC, the PI3K isoform inhibitors, AKTs, mTORs, and other components of the pathway were being actively pursued for targeted cancer therapies [28]. Here, PIK3CG is linked to nonpapillary renal cell carcinoma.